Genmab (GMAB) Panoramica del titolo
Genmab A/S, società di biotecnologie, sviluppa in Danimarca prodotti e candidati prodotti a base di anticorpi per il trattamento del cancro e di altre malattie. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 2/6 |
| Crescita futura | 3/6 |
| Prestazioni passate | 1/6 |
| Salute finanziaria | 2/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
GMAB Community Fair Values
Create NarrativeSee what 143 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Genmab A/S
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | DKK 2,151.00 |
| Massimo di 52 settimane | DKK 2,257.00 |
| Minimo di 52 settimane | DKK 1,512.00 |
| Beta | 0.69 |
| Variazione di 1 mese | 14.51% |
| Variazione a 3 mesi | 24.01% |
| Variazione di 1 anno | 36.61% |
| Variazione a 3 anni | -18.21% |
| Variazione a 5 anni | -28.73% |
| Variazione dall'IPO | 823.18% |
Notizie e aggiornamenti recenti
Aggiornamento narrativa • Aug 21
GMAB: Upcoming Oncology Readouts Will Support Commercial Transition And Offset Patent Cliff
Genmab's updated analyst price target has shifted modestly to DKK 2,930, as analysts factor in higher assumed revenue growth, a slightly lower profit margin profile, a higher discount rate and a lower future P/E multiple, supported by recent research citing confidence in Epkinly, rinatabart sesutecan and petosemtamab, stronger Q2 results, raised 2026 guidance and inclusion on a conviction list. Analyst Commentary Recent Street research on Genmab points to a cluster of supportive views, with several bullish analysts lifting price targets and upgrading ratings following Q2 results, updated 2026 guidance and progress across key oncology assets.Articolo di analisi • Aug 09
Genmab A/S Just Beat EPS By 29%: Here's What Analysts Think Will Happen Next
It's been a good week for Genmab A/S ( CPH:GMAB ) shareholders, because the company has just released its latest...
Aggiornamento narrativa • Aug 07
GMAB: 2026 Oncology Readouts Will Expose Darzalex Patent Cliff Risk
Analysts have raised Genmab’s fair value estimate from DKK 1,588.21 to DKK 1,634.61, citing higher price targets following recent research updates that emphasize robust Q2 results, increased 2026 guidance and growing confidence in the company’s oncology pipeline. Analyst Commentary Recent Street research on Genmab shows a mix of optimism around the oncology pipeline alongside more cautious views that focus on execution risks, valuation and upcoming data readouts.Recent updates
Aggiornamento narrativa • Aug 21
GMAB: Upcoming Oncology Readouts Will Support Commercial Transition And Offset Patent Cliff
Genmab's updated analyst price target has shifted modestly to DKK 2,930, as analysts factor in higher assumed revenue growth, a slightly lower profit margin profile, a higher discount rate and a lower future P/E multiple, supported by recent research citing confidence in Epkinly, rinatabart sesutecan and petosemtamab, stronger Q2 results, raised 2026 guidance and inclusion on a conviction list. Analyst Commentary Recent Street research on Genmab points to a cluster of supportive views, with several bullish analysts lifting price targets and upgrading ratings following Q2 results, updated 2026 guidance and progress across key oncology assets.Articolo di analisi • Aug 09
Genmab A/S Just Beat EPS By 29%: Here's What Analysts Think Will Happen Next
It's been a good week for Genmab A/S ( CPH:GMAB ) shareholders, because the company has just released its latest...Aggiornamento narrativa • Aug 07
GMAB: 2026 Oncology Readouts Will Expose Darzalex Patent Cliff Risk
Analysts have raised Genmab’s fair value estimate from DKK 1,588.21 to DKK 1,634.61, citing higher price targets following recent research updates that emphasize robust Q2 results, increased 2026 guidance and growing confidence in the company’s oncology pipeline. Analyst Commentary Recent Street research on Genmab shows a mix of optimism around the oncology pipeline alongside more cautious views that focus on execution risks, valuation and upcoming data readouts.
Aggiornamento narrativa • Jul 22
GMAB: Epkinly Franchise Progress Will Drive 2026 Catalyst-Rich Bullish Outlook
Analysts have lifted the Genmab fair value estimate from DKK 2,313.13 to DKK 2,392.08, reflecting updated assumptions around Epkinly's approval odds, the potential of rinatabart sesutecan and petosemtamab to help address the Darzalex patent cliff, and Genmab's inclusion on a conviction list alongside other Buy-rated stocks. Analyst Commentary Recent Street research on Genmab highlights a mix of optimism around its pipeline and questions about execution risk, especially as the company works to address the Darzalex patent expiry and transition further toward a commercially focused model.Aggiornamento narrativa • Jun 25
GMAB: Upcoming Oncology Readouts Will Test Commercial Model And Earnings Resilience
Genmab's analyst price targets have been revised lower, with one recent DKK target cut from DKK 48 to DKK 40, as analysts factor in updated assumptions for revenue growth, margins and long term P/E. They still point to the company's shift toward a commercially driven platform and upcoming data readouts for Epkinly, Rina-S and petosemtamab as key drivers in the story.Aggiornamento narrativa • Jun 10
GMAB: 2026 Readouts And Commercial Pivot Will Shape Bullish Outlook
Genmab’s consensus analyst price target has been reset lower from DKK 2,233 to DKK 2,313, with analysts citing a more commercially focused platform, evolving assumptions for revenue growth and margins, and updated P/E expectations following recent research on key pipeline readouts and price target revisions. Analyst Commentary Recent research on Genmab reflects a mix of optimism around the product pipeline and caution around valuation assumptions and execution risks.Aggiornamento narrativa • May 26
GMAB: Late Stage Oncology Readouts Will Support Stronger Margins And Earnings Quality
Genmab's analyst price target has been trimmed slightly to DKK 3,000, as analysts factor in more measured revenue growth expectations, a modestly higher discount rate, and a somewhat richer forward P/E outlook. They are still pointing to solid margin potential and recent bullish rating updates from several firms.Articolo di analisi • May 15
There May Be Some Bright Spots In Genmab's (CPH:GMAB) Earnings
The most recent earnings report from Genmab A/S ( CPH:GMAB ) was disappointing for shareholders. While the headline...Articolo di analisi • May 11
Analyst Estimates: Here's What Brokers Think Of Genmab A/S (CPH:GMAB) After Its First-Quarter Report
Genmab A/S ( CPH:GMAB ) shareholders are probably feeling a little disappointed, since its shares fell 3.9% to kr.1,642...Aggiornamento narrativa • Apr 29
GMAB: 2026 Pipeline Catalysts Will Test Balanced Risk And Opportunity Outlook
Narrative Update on Genmab The updated analyst framework lifts Genmab's fair value estimate from DKK 1,300 to about DKK 1,588. This reflects higher assumed revenue growth and P/E multiples as analysts factor in recent upgrades, resumed coverage and new acquisition driven pipeline contributions.Aggiornamento narrativa • Apr 15
GMAB: 2026 Clinical Readouts And AI Use Will Shape Outlook
Genmab's updated analyst price target edges slightly lower to DKK 2,233 from DKK 2,238, as analysts factor in mixed views around Epkinly assumptions, acquisition driven pipeline updates, and a modestly higher future P/E expectation despite broadly constructive long term growth potential. Analyst Commentary Recent research on Genmab reflects a mix of optimism around the expanded pipeline and upcoming catalysts, alongside caution tied to Epkinly assumptions and valuation.Aggiornamento narrativa • Mar 31
GMAB: 2026 Late Stage Oncology Catalysts Will Support Stronger Margin Profile
Genmab's updated analyst price target now sits at DKK 3,017, a modest reset from DKK 3,060 as analysts factor in higher discount rates, revised long term margin expectations, and recent research that reflects both increased revenue growth assumptions and a lower future P/E multiple. Analyst Commentary Recent Street research around Genmab has centered on how new clinical and portfolio developments filter into valuation, with several bullish analysts updating price targets and investment cases to reflect revised expectations on execution and long term growth potential.Aggiornamento narrativa • Mar 17
GMAB: 2026 Catalyst Calendar Will Likely Expose Downside Risk Ahead
Analysts have lifted the Genmab fair value estimate from DKK 1,075.93 to DKK 1,300.00, reflecting updated views on revenue growth, profitability and future P/E, following recent price target revisions and renewed coverage across the Street. Analyst Commentary Recent Street research on Genmab points to a mix of optimism and caution, with valuation views reset around updated expectations for key pipeline assets and royalty streams.Aggiornamento narrativa • Mar 03
GMAB: 2026 Catalyst Events And AI Adoption Will Shape Outlook
Genmab's analyst fair value estimate has moved up from DKK 2,182 to DKK 2,238, as analysts factor in higher long term revenue growth assumptions, a higher future P/E and recent price target revisions around DKK 2,400 to DKK 2,500, even as they temper near term expectations for Epkinly and margins. Analyst Commentary Recent research points to a more nuanced view of Genmab, with several firms adjusting their price targets and models following the latest earnings, product updates and acquisition activity.Aggiornamento narrativa • Feb 17
GMAB: 2026 Pipeline Readouts And AI Use Will Drive Outlook
Analysts have made a small trim to their blended DKK price target on Genmab, with the model now pointing to roughly DKK 2,182. This reflects updated assumptions around slightly higher discount rates, a modestly different margin outlook and a lower future P/E multiple after recent coverage resets and target hikes from banks like Morgan Stanley, Deutsche Bank and Barclays.Aggiornamento narrativa • Feb 02
GMAB: Phase 3 Data, AI Adoption And 2026 Readout Will Shape Outlook
Genmab’s analyst fair value estimate has moved modestly higher to DKK 2,188.94. Analysts point to updated assumptions around slightly lower discount rates, adjusted revenue growth and profit margin expectations, and a recalibrated future P/E multiple as the key drivers behind the refreshed price targets.Aggiornamento narrativa • Jan 19
GMAB: Phase 3 Setback And 2026 Readout Will Shape Market Outlook
Genmab’s analyst price target has been lifted by roughly DKK 100 to reflect updated expectations around slightly higher revenue growth and profit margin assumptions, as analysts point to recent target increases from DKK 2,000 to DKK 2,400 and DKK 2,500 as support for a higher fair value range. Analyst Commentary Recent Street research on Genmab reflects a generally constructive stance, with higher price targets and continued attention on upcoming clinical milestones.Aggiornamento narrativa • Jan 05
GMAB: Late Stage Oncology Focus Will Drive Stronger Margins And Repricing
Analysts have increased their fair value estimate for Genmab from DKK 2,700 to approximately DKK 3,060, reflecting updated assumptions that combine lower projected revenue growth with higher profit margins and a reduced future P/E multiple. What's in the News Genmab plans to discontinue further clinical development of acasunlimab and to concentrate resources on late stage programs such as EPKINLY (epcoritamab), petosemtamab and rinatabart sesutecan, described as part of its disciplined portfolio and capital allocation framework (Key Developments).Aggiornamento narrativa • Dec 14
GMAB Merus Deal Will Likely Expose Downside Risk At Current Levels
Analysts have lifted Genmab's fair value estimate from DKK 1,015 to about DKK 1,076, reflecting a series of higher price targets that cite the Merus acquisition's boost to the late stage pipeline and underappreciated royalty revenue upside as key drivers. Analyst Commentary Recent Street research on Genmab remains broadly constructive, with multiple firms lifting price targets and highlighting the strategic merits of the Merus acquisition.Aggiornamento narrativa • Nov 29
GMAB: Merus Acquisition and Pipeline Depth Will Shape Market Outlook
Genmab's analyst price target has seen a modest decrease of approximately DKK 3.57 to DKK 2,054.66. Analysts are factoring in sustaining growth drivers from recent pipeline acquisitions while adjusting for updates to discount rate and margin assumptions.Aggiornamento narrativa • Nov 15
GMAB: Future Pipeline Expansion and Merus Acquisition Will Define Performance
Genmab's analyst price target has been raised from approximately DKK 2,017 to DKK 2,058. This reflects analysts' increased confidence in the company's pipeline expansion, notably following the Merus acquisition and upside potential from key assets such as Epkinly.Aggiornamento narrativa • Nov 01
GMAB: Recent Acquisition Will Drive Pipeline Expansion While Integration Risks Remain
Genmab's fair value estimate has been raised from DKK 2,012.92 to DKK 2,017.35. Analysts highlight the Merus acquisition's positive impact on the late-stage pipeline and renewed confidence in royalty revenue growth opportunities.Aggiornamento narrativa • Oct 18
Pipeline Progress And International Expansion Will Unlock Market Opportunities
Genmab's analyst fair value target has increased slightly, rising from DKK 2,005 to DKK 2,013. Analysts cite royalty revenue upside and pipeline expansion following recent M&A activity as key drivers for the upward revisions.Aggiornamento narrativa • Oct 04
Pipeline Progress And International Expansion Will Unlock Market Opportunities
Genmab's analyst price target was raised from approximately $1,942 to $2,005. This reflects increased confidence among analysts in the company's growth outlook and pipeline expansion following recent acquisitions.Articolo di analisi • Sep 24
Here's Why We Think Genmab (CPH:GMAB) Might Deserve Your Attention Today
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Aggiornamento narrativa • Sep 04
Pipeline Progress And International Expansion Will Unlock Market Opportunities
Genmab’s consensus price target was unchanged at DKK1942, as strong sales momentum and positive pipeline updates were offset by concerns about rising competition and tempered long-term growth expectations. Analyst Commentary Bullish analysts are raising price targets following stronger-than-expected sales momentum for Genmab's key oncology products.
Nuova narrativa • Nov 11
Decisive Advances And DuoBody Innovation Propel Future Growth In Biotech Frontiers
Genmab's focus on late-stage therapies, particularly EPKINLY, is expected to boost future revenue and growth due to best-in-class technology and market approvals.Rendimenti per gli azionisti
| GMAB | DK Biotechs | DK Mercato | |
|---|---|---|---|
| 7D | 2.2% | 3.0% | 0.8% |
| 1Y | 36.6% | 17.9% | -0.4% |
Ritorno vs Industria: GMAB ha superato il Danish Biotechs che ha restituito 17.9 % nell'ultimo anno.
Rendimento vs Mercato: GMAB ha superato il mercato Danish che ha restituito -0.4 % nell'ultimo anno.
Volatilità dei prezzi
| GMAB volatility | |
|---|---|
| GMAB Average Weekly Movement | 4.9% |
| Biotechs Industry Average Movement | 7.3% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in DK Market | 7.5% |
| 10% least volatile stocks in DK Market | 2.5% |
Prezzo delle azioni stabile: GMAB non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato Danish.
Volatilità nel tempo: La volatilità settimanale ( 5% ) di GMAB è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1998 | 3,119 | Jan G.J. de Winkel | www.genmab.com |
Genmab A/S, azienda biotecnologica, sviluppa prodotti e candidati prodotti a base di anticorpi per il trattamento del cancro e di altre malattie in Danimarca. L'azienda commercializza EPKINLY e TEPKINLY per pazienti adulti affetti da linfoma diffuso a grandi cellule B (DLBCL), linfoma a grandi cellule B e linfoma follicolare (FL) recidivato o refrattario (R/R); e Tivdak per pazienti adulti affetti da carcinoma cervicale ricorrente/metastatico con progressione della malattia durante o dopo la chemioterapia. Sta inoltre sviluppando Epcoritamab per DLBCL e FL R/R, DLBCL e FL di prima linea, linfoma non-Hodgkin a cellule B, leucemia linfocitica cronica R/R e sindrome di Richter e neoplasie aggressive a cellule B mature in pazienti pediatrici; tisotumab vedotin per i tumori solidi; Acasunlimab per i tumori solidi e il carcinoma polmonare non a piccole cellule (NSCLC); Rinatabart Sesutecan per il carcinoma ovarico e i tumori solidi resistenti al platino; GEN1042, GEN1059, GEN1055 e GEN1057 per i tumori solidi; GEN3014 per le neoplasie ematologiche; GEN1160 per i tumori solidi e liquidi avanzati; GEN1107 e GEN1286 per i tumori solidi avanzati.
Genmab A/S Riepilogo dei fondamenti
| GMAB statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | DKK 128.42b |
| Utili (TTM) | DKK 5.04b |
| Ricavi(TTM) | DKK 26.44b |
25.5x
Rapporto P/E4.9x
Rapporto P/SGMAB è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| GMAB Conto economico (TTM) | |
|---|---|
| Ricavi | US$4.13b |
| Costo del fatturato | US$288.00m |
| Profitto lordo | US$3.84b |
| Altre spese | US$3.06b |
| Utili | US$788.00m |
Ultimi utili riportati
Jun 30, 2026
Prossima data di guadagno
Nov 05, 2026
| Utile per azione (EPS) | 13.20 |
| Margine lordo | 93.03% |
| Margine di profitto netto | 19.08% |
| Rapporto debito/patrimonio netto | 86.2% |
Come si è comportato GMAB nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/24 09:07 |
| Prezzo dell'azione a fine giornata | 2026/08/21 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Genmab A/S è coperta da 38 analisti. 20 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| James Gordon | Barclays |
| Xue Chen | Barclays |
| Emily Field | Barclays |